✦ LIBER ✦

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors

✍ Scribed by Stewart, Clinton F.; Tagen, Michael; Schwartzberg, Lee S.; Blakely, L. Johnetta; Tauer, Kurt W.; Smiley, Linda M.

Book ID: 121544947
Publisher: Springer
Year: 2014
Tongue: English
Weight: 408 KB
Volume: 73
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2385-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of the combination of topo

Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors

✍ Carlos Rodriguez-Galindo; Kristine R. Crews; Clinton F. Stewart; Wayne Furman; J 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 271 KB

Phase I study of docetaxel and topotecan

Phase I study of docetaxel and topotecan in patients with solid tumors

✍ Katherine H. Tkaczuk; William C. Zamboni; Nancy S. Tait; Barry R. Meisenberg; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 103 KB

Phase I and pharmacokinetic study of sor

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

✍ Hironobu Minami; Kenji Kawada; Hiromichi Ebi; Koichi Kitagawa; Yon-il Kim; Kazuh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

A phase I dose-escalation and pharmacoki

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors

✍ Sukhmani K. Padda; Yelena Krupitskaya; Laveena Chhatwani; George A. Fisher; Alex 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 281 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A phase I study of sequential administra

A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors

✍ Caio M. S. Rocha Lima; Carlo V. Catapano; Daniel Pacheco; Carol A. Sherman; Greg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and dose‐limiting toxicities (DLTs) associated with a sequential combination of